Aliaa Mohammed Mahmoud Soliman

Aliaa Mohammed Mahmoud Soliman

Auto-generated profile, based on publicly available information

Aliaa Mohammed Mahmoud Soliman

Department of Psychology and Counseling, Austin Peay State University, Clarksville, TN, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2025 in Journal of Medicine and Health Research
Verified
Journal Article
Closed access
EFEvelyn Foster-Pagaebi
Evelyn Foster-Pagaebi
KZKefas Paul Zawaya
Kefas Paul Zawaya
CBCephas Biya
Cephas Biya
NENneji Nmesomachukwu Eneda
Nneji Nmesomachukwu Eneda
ASAliaa Mohammed Mahmoud Soliman
Aliaa Mohammed Mahmoud Soliman
JPJohn Opeyemi Patrick
John Opeyemi Patrick
Background: Health equity and universal health coverage are critical global health priorities, especially with regard to the 2030 Sustainable Development Goals. Yet, systemic obstacles exist, impeding billions from accessing essential healthcare services, particularly in low- and middle-income countries. Purpose of the Study: This study explores the pivotal role of community healthcare systems as the strategy for achieving health equity and universal health coverage, framed within social justice and primary healthcare principles. Methodology: A review and synthesis of global, regional and country specific evidences, along with policy frameworks and best practices was conducted using databases such as PubMed, Google Scholar, CINAHL, PsycINFO, Scopus, WHO and UNAIDS websites. The results were analyzed and only relevant and evidence-based studies were included in the study. Findings: Evidence from high-income, low-and middle-income countries underscore the crucial role community-based health systems play in providing accessible, culturally appropriate, and cost-efficient healthcare to communities around the world. Key barriers were identified. However, evidenced-based and innovative solutions exist. Policy recommendations emphasize recruitment, training and integration of community health workers into national health systems, inclusive financing, investment in digital infrastructure, and cross-sectoral collaborations. Conclusion: Effective community healthcare systems have resulted in significant increase in service use, and has bridged the health disparity gaps in local communities. This positions community healthcare as a strategic pivot to achieving health equity and sustainable health for all.

19 September 2025 in Australian Journal of Biomedical Research
Verified
Journal Article
Open access
PDF file
SASalvation Ifechukwude Atalor
Salvation Ifechukwude Atalor
ASAliaa Mohammed Mahmoud Soliman
Aliaa Mohammed Mahmoud Soliman
OAOluwatobiloba Kehinde Adedokun
Oluwatobiloba Kehinde Adedokun
AAAbayomi Modinat Aina
Abayomi Modinat Aina
CUCecilia Chika Unegbu
Cecilia Chika Unegbu
AOALIYU OLANREWAJU OLANIYI
ALIYU OLANREWAJU OLANIYI
Background: Small-molecule drugs have transformed oncology, but conventional inhibitors are limited by resistance, restricted target scope, and declining durability. Methods: We reviewed emerging small-molecule modalities—molecular glues, covalent inhibitors, and radiotheranostics—focusing on their mechanisms, clinical applications, and translational challenges. Key clinical trials and representative examples were identified from recent oncology literature. Results: Molecular glues enable targeted degradation of previously undruggable proteins, with clinical success in multiple myeloma (IMiDs). Covalent inhibitors achieve durable suppression of oncogenic drivers such as KRAS^G12C and BTK, as shown in CodeBreaK100 (sotorasib; N=126; ORR 37%). Radiotheranostics combine imaging and therapy, exemplified by VISION (PSMA-617; N=831; OS HR 0.62) and NETTER-1 (Lutathera; N=229; PFS HR 0.21). Collectively, these modalities expand the druggable proteome, improve durability, and advance precision oncology. Conclusion: Emerging small-molecule approaches mark a paradigm shift from inhibition alone to targeted degradation, durable covalent engagement, and diagnostic–therapeutic hybrids. Future priorities include improving selectivity, biomarker integration, scalable manufacturing, and equitable global access.

4 June 2025 in Journal of Cancer and Tumor International
Verified
Journal Article
Closed access
FEFortune Itoje Ebiala
Fortune Itoje Ebiala
JOJumoke Ologun
Jumoke Ologun
JIJohn Kelenna Iregbu
John Kelenna Iregbu
OCOgochi Blessing Chukwuneke
Ogochi Blessing Chukwuneke
ASAliaa Mohammed Mahmoud Soliman
Aliaa Mohammed Mahmoud Soliman
LALawrence John Ajutor
Lawrence John Ajutor
Background: Oncogene addiction occurs in most tumour cells it is a phenomenon capable of driving colorectal cancer (CRC) growth, where tumour cells rely on genes like KRAS, BRAF, or MYC to survive. This has been so far seen as an exploitable target for precision therapies. Aim: This review examines how CRISPR-based gene editing strategies can be used to disrupt oncogene addiction in CRC, with a keen focus on their therapeutic potential. Methodology: A systematic review of recent studies, retrieved from reputable databases including PubMed and Google Scholar was conducted. Data from CRISPR/Cas9 and other CRISPR-based applications targeting key oncogenes in CRC models were collected. Findings Results: Findings show that CRISPR/Cas9-mediated knockout of specific oncogenes such as mutations of KRAS or BRAF were able to disrupt tumour-dependent MAPK/ERK signalling, reducing tumour growth in 60–80% of preclinical CRC models. Other innovative CRISPR-stimulated applications like Base editing showed efficacy in correcting specific mutations like KRAS G12D, restoring normal gene function, while prime editing addresses complex mutations with high precision, achieving high efficiency in organoids. CRISPR interference (CRISPRi) downregulates MYC expression without permanent DNA changes, inhibiting proliferation in CRC cell lines. Combining CRISPR with small molecule inhibitors, such as MEK inhibitors, enhances tumour suppression by 30–50% in mouse models by targeting compensatory pathways. Additionally, CRISPR-edited tumour-infiltrating lymphocytes (TILs) improve immunotherapy responses in early-phase trials (e.g., NCT04426669). However, challenges reported include off-target edits, which occur in 5–10% of CRISPR/Cas9 applications, and poor delivery to solid CRC tumours due to dense stroma. Tumour heterogeneity complicates targeting, as subpopulations may rely on different oncogenes. Ethical concerns and regulatory hurdles, such as ensuring safety and equitable access still needs to be addressed before clinical translation. Conclusion: Ongoing studies are exploring high-fidelity CRISPR variants and tumour-targeted nanoparticles to improve specificity and delivery. Innovative next-generation tools are being explored, like Cas13 for RNA editing, integration with liquid biopsies for personalized mutation targeting, and combining CRISPR with immunotherapies to overcome resistance. These advancements position CRISPR as a promising approach to revolutionize CRC treatment by precisely targeting oncogene addiction, provided delivery and safety challenges are addressed.